PMC3360199_01
Somatostatin receptor scintigraphy (111In-DTPA-octreotide, OctreoScan ) in March 2009; Whole body scan, anterior and posterior view.
thnov02p0459g01.jpg
PMC3360199_01_thnov02p0459g01.jpg
F1
Somatostatin receptor scintigraphy in March 2009 showed very high uptake in all known tumour lesions (Figure 1).
Glomerular filtration rate (GFR) according to the Cystatin C method, S-albumin and S-creatinine as a function of treatment.
thnov02p0459g02.jpg
PMC3360199_01_thnov02p0459g02.jpg
F2
The tumour burden in the liver had grown abundant by this time, engaging more than 50% of the total volume with decreasing liver function (Figure 2) and chemotherapy was stopped. By then, the glomerular filtration rate had decreased from already subnormal values (normal range, age adjusted >80 ml/min/1,73m2) at the time of diagnosis down to 41 ml/min/1,73m2 before the first cycle (Figure 2).
Blood cell counts during therapy with 177Lu-DOTA-octreotate.
thnov02p0459g03.jpg
PMC3360199_01_thnov02p0459g03.jpg
F3
September 2010, following the second cycle of 177Lu-DOTA-octreotate, she had a sudden drop in platelets, as part of a paramalignant phenomenon. She recovered after several weeks of prednisolone and fraxiparine; later cycles of PRRT were administered without any delay (Figure 3).